R. Laurita , M. Gherardi , A. Stancampiano , A. Miserocchi , A.M. Porcelli , A.M. Perrone , V. Colombo , G. Gasparre , P. De Iaco
{"title":"AlmaIDEA项目:血浆活化液抗肿瘤活性背后的化学物理和生物学机制，用于治疗原始上皮性卵巢/小管肿瘤腹膜癌","authors":"R. Laurita , M. Gherardi , A. Stancampiano , A. Miserocchi , A.M. Porcelli , A.M. Perrone , V. Colombo , G. Gasparre , P. De Iaco","doi":"10.1016/j.cpme.2017.12.062","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Advanced ephitelial ovarian cancer is characterized by the diffusion of the disease as nodules or plaques from the ovary to peritoneal surfaces (carcinosis) (Fig.1). In advanced stages the disease presents poor prognosis (OS Figo stage III-IV: 15-20% within 5 years) [1]. Nowadays, multimodal treatments, surgery and intravenous/intraperitoneal chemotherapy with platinum and taxanes, can increase the survival rate but not eradicate the disease and about 80% of patients relapse ), because chemotherapeutic agents show low efficacy against resistant tumor subclones. For this reason, there is a continuous need for novel therapies. Since the treatment of liquids by means of cold atmospheric pressure plasma enables the production of plasma activated liquids (PALs) containing reactive oxygen and nitrogen species (RONS) having </span>antitumor activity<span><span> [2-3], the direct application of PALs on peritoneal surfaces could represents an alternative treatment of carcinosis. In this context, the aim of this work is to present preliminary results on the effect of PALs on human ovarian </span>carcinoma cells </span></span><em>in vitro.</em> The research is performed in the frame of the Alma<em>IDEA</em><span><span><span> project focused on the investigation of PALs (plasma activated liquids) as potential antitumor agent in the treatment of peritoneal carcinosis (Fig.1). The composition of the team, that brings together surgeons of </span>gynecologic oncology, geneticists (with a bias on </span>mitochondrial metabolism in solid tumors) and plasma engineers, allows to have a multidisciplinary approach to the research, whose final aim is the development of a novel intraperitoneal therapy for cancer treatment, starting from the investigation of the bio-chemical effect of PALs on cells </span><em>in vitro</em>.<span><figure><span><img><ol><li><span>Download : <span>Download high-res image (361KB)</span></span></li><li><span>Download : <span>Download full-size image</span></span></li></ol></span></figure></span></p><p>Figure 1: Peritoneal carcinosis (red arrows) close to ovary (right) and PAL production using microsecond pulsed DBD jet (left).</p></div>","PeriodicalId":46325,"journal":{"name":"Clinical Plasma Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cpme.2017.12.062","citationCount":"0","resultStr":"{\"title\":\"AlmaIDEA Project: Chemo-Physical And Biological Mechanisms Behind The Antitumor Activity Of Plasma Activated Liquids For The Treatment Of Peritoneal Carcinosis From Primitive Epithelial Ovarian/Tubular Tumor\",\"authors\":\"R. Laurita , M. Gherardi , A. Stancampiano , A. Miserocchi , A.M. Porcelli , A.M. Perrone , V. Colombo , G. Gasparre , P. De Iaco\",\"doi\":\"10.1016/j.cpme.2017.12.062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Advanced ephitelial ovarian cancer is characterized by the diffusion of the disease as nodules or plaques from the ovary to peritoneal surfaces (carcinosis) (Fig.1). In advanced stages the disease presents poor prognosis (OS Figo stage III-IV: 15-20% within 5 years) [1]. Nowadays, multimodal treatments, surgery and intravenous/intraperitoneal chemotherapy with platinum and taxanes, can increase the survival rate but not eradicate the disease and about 80% of patients relapse ), because chemotherapeutic agents show low efficacy against resistant tumor subclones. For this reason, there is a continuous need for novel therapies. Since the treatment of liquids by means of cold atmospheric pressure plasma enables the production of plasma activated liquids (PALs) containing reactive oxygen and nitrogen species (RONS) having </span>antitumor activity<span><span> [2-3], the direct application of PALs on peritoneal surfaces could represents an alternative treatment of carcinosis. In this context, the aim of this work is to present preliminary results on the effect of PALs on human ovarian </span>carcinoma cells </span></span><em>in vitro.</em> The research is performed in the frame of the Alma<em>IDEA</em><span><span><span> project focused on the investigation of PALs (plasma activated liquids) as potential antitumor agent in the treatment of peritoneal carcinosis (Fig.1). The composition of the team, that brings together surgeons of </span>gynecologic oncology, geneticists (with a bias on </span>mitochondrial metabolism in solid tumors) and plasma engineers, allows to have a multidisciplinary approach to the research, whose final aim is the development of a novel intraperitoneal therapy for cancer treatment, starting from the investigation of the bio-chemical effect of PALs on cells </span><em>in vitro</em>.<span><figure><span><img><ol><li><span>Download : <span>Download high-res image (361KB)</span></span></li><li><span>Download : <span>Download full-size image</span></span></li></ol></span></figure></span></p><p>Figure 1: Peritoneal carcinosis (red arrows) close to ovary (right) and PAL production using microsecond pulsed DBD jet (left).</p></div>\",\"PeriodicalId\":46325,\"journal\":{\"name\":\"Clinical Plasma Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cpme.2017.12.062\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Plasma Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212816617300872\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Plasma Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212816617300872","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
AlmaIDEA Project: Chemo-Physical And Biological Mechanisms Behind The Antitumor Activity Of Plasma Activated Liquids For The Treatment Of Peritoneal Carcinosis From Primitive Epithelial Ovarian/Tubular Tumor
Advanced ephitelial ovarian cancer is characterized by the diffusion of the disease as nodules or plaques from the ovary to peritoneal surfaces (carcinosis) (Fig.1). In advanced stages the disease presents poor prognosis (OS Figo stage III-IV: 15-20% within 5 years) [1]. Nowadays, multimodal treatments, surgery and intravenous/intraperitoneal chemotherapy with platinum and taxanes, can increase the survival rate but not eradicate the disease and about 80% of patients relapse ), because chemotherapeutic agents show low efficacy against resistant tumor subclones. For this reason, there is a continuous need for novel therapies. Since the treatment of liquids by means of cold atmospheric pressure plasma enables the production of plasma activated liquids (PALs) containing reactive oxygen and nitrogen species (RONS) having antitumor activity [2-3], the direct application of PALs on peritoneal surfaces could represents an alternative treatment of carcinosis. In this context, the aim of this work is to present preliminary results on the effect of PALs on human ovarian carcinoma cells in vitro. The research is performed in the frame of the AlmaIDEA project focused on the investigation of PALs (plasma activated liquids) as potential antitumor agent in the treatment of peritoneal carcinosis (Fig.1). The composition of the team, that brings together surgeons of gynecologic oncology, geneticists (with a bias on mitochondrial metabolism in solid tumors) and plasma engineers, allows to have a multidisciplinary approach to the research, whose final aim is the development of a novel intraperitoneal therapy for cancer treatment, starting from the investigation of the bio-chemical effect of PALs on cells in vitro.
Download : Download high-res image (361KB)
Download : Download full-size image
Figure 1: Peritoneal carcinosis (red arrows) close to ovary (right) and PAL production using microsecond pulsed DBD jet (left).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
